Researchers in Montreal reported that the interaction between diet and gut microbiota may explain why patients with obesity often respond more favorably to immunotherapy.
The study suggests that this diet‑microbiota interplay could be a factor influencing the varying outcomes of immunotherapy, particularly among individuals with a high body mass index. Immunotherapy effectiveness is known to differ among cancer patients, and obesity has occasionally been associated with improved treatment responses despite its usual health risks.